X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/aasld-gilead-wants-to-move-needle-for-fatty-liver-therapies
https://www.reuters.com/article/us-gilead-sciences-nash/gilead-experimental-nash-drug-fails-another-study-idUSKCN1S11IM?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/us-gilead-sciences-insitro-nash/gilead-teams-up-with-insitro-for-experimental-nash-treatments-idUSKCN1RS11J?feedType=RSS&feedName=healthNews
https://endpts.com/team-building-pipeline-revamp-forward-thrust-what-does-a-decade-of-deals-at-gilead-tell-us-about-daniel-odays-first-moves/
https://www.reuters.com/article/us-gileadsciences-nash/gilead-misses-key-goal-in-nash-liver-disease-trial-shares-sink-idUSKCN1Q02HU
https://endpts.com/whats-up-with-all-the-buzz-about-gileads-phiii-nash-drug-selonsertib/
https://seekingalpha.com/article/4233225-2019-turnaround-year-gilead-sciences
https://www.biopharmadive.com/news/nash-2019-jpm-readouts-deals-market-competition/545772/
https://endpts.com/gilead-stuffs-another-nash-drug-discovery-program-into-a-growing-portfolio/
https://www.biospace.com/article/is-gilead-poised-for-a-comeback-/
https://www.fiercebiotech.com/jefferies-says-gilead-poised-for-turnaround-and-jak-inhibitor-could-be-key
Market Place
Share 
